FOLH1 and prostate cancer: A prospective study comparing 68Ga-PSMA-11 PET/CT and conventional imaging in high-risk prostate cancer found that PSMA PET/CT detected metastases in 27% of cases previously classified as localized, leading to treatment modifications in 28% of patients [12].